| Therapeutic depletion of CCR8+ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy H Van Damme, B Dombrecht, M Kiss, H Roose, E Allen, E Van Overmeire, ... Journal for immunotherapy of cancer 9 (2), 2021 | 111 | 2021 |
| Macrophages are metabolically heterogeneous within the tumor microenvironment X Geeraerts, J Fernandez-Garcia, FJ Hartmann, KE de Goede, L Martens, ... Cell reports 37 (13), 2021 | 81 | 2021 |
| IL1β promotes immune suppression in the tumor microenvironment independent of the inflammasome and gasdermin D M Kiss, L Vande Walle, PHV Saavedra, E Lebegge, H Van Damme, ... Cancer immunology research 9 (3), 309-323, 2021 | 51 | 2021 |
| Diamonds in the rough: harnessing tumor-associated myeloid cells for cancer therapy EJ Clappaert, A Murgaski, H Van Damme, M Kiss, D Laoui Frontiers in immunology 9, 2250, 2018 | 41 | 2018 |
| Stromal-targeting radioimmunotherapy mitigates the progression of therapy-resistant tumors E Bolli, M D’Huyvetter, A Murgaski, D Berus, G Stangé, EJ Clappaert, ... Journal of controlled release 314, 1-11, 2019 | 26 | 2019 |
| Unleashing tumour-dendritic cells to fight cancer by tackling their three A’s: abundance, activation and antigen-delivery A Murgaski, PMR Bardet, SM Arnouk, EJ Clappaert, D Laoui Cancers 11 (5), 670, 2019 | 16 | 2019 |
| Efficacy of CD40 agonists is mediated by distinct cDC subsets and subverted by suppressive macrophages A Murgaski, M Kiss, H Van Damme, D Kancheva, I Vanmeerbeek, ... Cancer Research 82 (20), 3785-3801, 2022 | 14 | 2022 |
| Junctional adhesion molecule-A is dispensable for myeloid cell recruitment and diversification in the tumor microenvironment M Kiss, E Lebegge, A Murgaski, H Van Damme, D Kancheva, ... Frontiers in immunology 13, 1003975, 2022 | 2 | 2022 |
| Inflammasome-and gasdermin D-independent IL-1β production mobilizes neutrophils to inhibit antitumor immunity M Kiss, L Vande Walle, E Lebegge, H Van Damme, A Murgaski, J Qian, ... bioRxiv, 2020.08. 04.235796, 2020 | 2 | 2020 |
| Vaccination with tumor-derived conventional type 2 dendritic cells delay spontaneous lung metastasis A Murgaski, L Allonsius, E Marcq, FA Nana, D Laoui European Macrophage and Dendritic Cell Society (EMDS) Meeting 2023, 2023 | | 2023 |
| Understanding the effect and mechanisms of CD40 agonist therapy on tumour growth and dendritic cell vaccination strategies A Murgaski | | 2022 |
| Distinct cDC subsets co-operate in CD40 agonist response while suppressive microenvironments and lack of antigens subvert efficacy A Murgaski, M Kiss, H Van Damme, D Kancheva, I Vanmeerbeek, ... bioRxiv, 2021.12. 25.474021, 2021 | | 2021 |
| IL1ß promotes immune suppression in the tumor microenvironment independent of the inflammasome and gasdermin D. M Kiss, L Vande Walle, PHV Saavedra, E Lebegge, H Van Damme, ... Cancer immunology res.(Online), 2020 | | 2020 |
| Inflammasome-independent IL-1 beta release by myeloid cells promotes vessel destabilization and immune suppression in the tumor microenvironment M Kiss, L Vande Walle, H Van Damme, A Murgaski, E Bolli, J Keirsse, ... Cancer Immunology Research 7 (2), 2019 | | 2019 |
| Abstract A083: Inflammasome-independent IL-1β release by myeloid cells promotes vessel destabilization and immune suppression in the tumor microenvironment M Kiss, LV Walle, HV Damme, A Murgaski, E Bolli, J Keirsse, MS Martins, ... Cancer Immunology Research 7 (2_Supplement), A083-A083, 2019 | | 2019 |
